The price has taken a big plunge! The price of N95, oximeter, etc. was reduced, and some fell by half
From ibuprofen, montmorillonite, gamma globulin, oximeter to coenzyme Q10, etc., epidemic prevention related drugs and medical devices have experienced different stages of urgent need, rush to purchase, price increase to price decline.
01
The flow of pharmacies in the tide of stockpiling skyrocketed
Nowadays, the price of oximeters, N95 and so on has plunged
Today (January 16), "N95 mask oximeter price plunge" rushed to Weibo hot search, many people complained about oximeter and N95 price reduction, the mood like stocks fell, and some people even said "diving is not as fast as your price reduction!" ”
As many places have successively announced that the peak of new crown virus infection has passed, the price of epidemic prevention supplies has also begun to plunge. Some manufacturers said to Cyborg Blue that the finger-clip oximeter is now 65 yuan / piece, which is much cheaper.
Half a month ago, when Cyborn asked the price of the manufacturer's oximeter, it was still 90 yuan per piece. More importantly, the list of the oximeter has arrived after the Spring Festival, and the manufacturer said that the amount is small and does not accept the order.
Now, in the face of the price of oximeter price plunge, the manufacturer said that "in fact, it is hot for a while." ”
On the Jingdong platform, with "oximeter" and "N95" as the keyword search found that most of the current is in stock, the price of the oximeter has also fallen back to more than 100 yuan, a blood oximeter with an evaluation of more than 1 million + (contec Kangtai monitoring oximeter) CMS50D is currently priced at 128 yuan / piece; The price of N95 masks has also appeared in independent packaging of 36 yuan, 50 pieces, the average price has been less than 1 yuan; There are also some N95 masks whose price is already 0.6 yuan per piece.
At the same time, during the "hoarding tide", the flow of customers in physical pharmacies skyrocketed, and many pharmacy staff were too busy to reply to messages.
As the enthusiasm for stockpiling cooled, the operator of a chain pharmacy in Hebei told Cyboran that "the flow of pharmacy customers is much less now", and Tang Ming, the owner of a single pharmacy in Jiangsu, also said: "It's not too busy recently, and the customer flow is much less." ”
Tang Ming revealed that among all kinds of epidemic prevention supplies that have risen in price, antigen detection reagents are the first to fall in price.
"My purchase price (2022) on December 6 is 2.3 yuan a piece." According to his recollection, he contacted the antigen manufacturer later, "(the manufacturer) directly did not accept orders, and could only 'pour' from other channels." ”
It was also from this time that the antigen purchase price began to rise, "about 5 yuan cheaper, and the expensive one heard that it was more than 8 yuan, and there were almost no tickets."
"About a week ago, it came back, and now the pharmacy buys almost 3 yuan."
In an online pharmacy, the price of antigen test reagent coupons for 25 people is less than 63 yuan, about 2.5 yuan per copy, which is lower than the purchase price of some pharmacies.
This was followed by a fall in the prices of four classes of drugs.
"Now there are almost no customers who stock up, very few, occasionally one or two to prepare diarrhea medicine", in terms of drug supply, "some best-selling, such as cold spirit granules, these are still out of stock, and others are almost available".
But there are some exceptions. Tang Ming said that children's antipyretic drugs, such as Merrill Lynch and Tylenolin, are still difficult to buy, and at the same time, this is also the category with the largest price fluctuation among the four types of drugs. "At the highest, it is about three or four times, for example, the purchase price of Merrill Lynch in 30ml is 25 yuan, and the most expensive time is more than 80 yuan."
Among the suppliers contacted by Tang Ming, "thermometers and oximeters are still more expensive than before", but judging from the trend of other products, he believes that "it is estimated that it will return to normal in a while".
02
The supply of montmorillonite scatters, masks, etc. has improved
Drugs with longer production cycles are still snapped up
For different epidemic prevention supplies, the reasons for the price decline are very different. Taking drugs as an example, the price increase in a short period of time should not only consider the market supply and demand, but also consider all links of the pharmaceutical production industry chain, such as the increase in the price of raw materials themselves, the production of pharmaceutical workers, logistics, packaging, etc.
Some drugs with shorter production cycles, such as montmorillonite, are supplied normally soon after a short period of stock-outs. As one of the manufacturers, Simcere Pharmaceutical once told Cyborg Blue that the entire montmorillonite bulk production cycle includes eight days, and the most important and time-consuming is the production of montmorillonite raw materials, which will be longer.
The same is true of "N95 masks", in the case of short supply, the price of masks soared, even known as "golden masks", after the rush to buy faded, the price gradually returned to normal, a large number of manufacturers in it have successively closed down or suspended production.
However, another issue to consider when stockpiling is product effectiveness. According to the reminder issued by "Wuhan Market Surveillance", the validity period of disposable masks is usually 2-3 years, and N95 masks are about 5 years.
At present, for epidemic prevention drugs and supplies with long production cycles, prices are still at a "high level". Recently, on social platforms, you can still see many people buying intravenous human immunoglobulin, and the price of the drug has risen directly from a few hundred yuan to more than 2,000 yuan.
CITIC Securities analyzed in a research report that considering that the production process of blood product manufacturers is not much different, it is estimated that the product production cycle of different blood product manufacturers will be relatively close, and the main factors affecting the length of product production cycle are product testing and batch issuance systems. According to the data released by Weiguang Biotechnology, after adding the finished product verification and batch issuance time, the production cycle of intravenous human immunoglobulin exceeds 100 days.
In addition, the search volume of "coenzyme Q10" has also skyrocketed in recent times, mainly because many people believe that coenzyme Q10 can prevent the occurrence of myocarditis after "Yangkang".
According to "News Jianwai No. 14", Ruan Guangfeng, deputy director of Kexin Food and Health Information Exchange Center and member of the Expert Committee of China Internet Joint Rumor Debunking Platform, explained that human life activities rely on many biochemical reactions, such as respiration, metabolism, etc., these metabolic reactions need enzymes to participate, and the role of enzymes is to make these reactions faster, better and more efficient, and coenzymes are actually the assistants of these enzymes, playing an auxiliary role. There are many types of coenzymes in the human body, and CoQ10 is just one of them.
Whether it is a drug or a medical device, there will never be a shortage of people in demand in the market, but whether everyone really needs it, it is still necessary to maintain a rational attitude. Following montmorillonite, norfloxacin, and intravenous human immunoglobulin being "heated" one after another, and gradually cooling, who will be the next to reduce the price?
Looking for chemical products? Let suppliers reach out to you!
2026-07-09
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
-
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR
-
Ribo Biologics announced that the world's first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia
Recommend Reading
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Evonik Cuts 3,200 Jobs: Europe’s Chemical Winter Is Not Over
-
Cyclohexane Market Supply and Demand Balance, Operating Steadily in China
-
INEOS Closes US Polystrene Plant: 400K Tons of PD in the US Can't Hold On
-
Weak and Volatile Ethanol Market in China
-
February Acetic Acid Market Fluctuates